Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide does not cause a false positive on standard workplace or forensic drug screening tests. It is not a controlled substance, does not share a chemical structure with anything those panels look for, and there is no published clinical evidence linking it to false positive results. That said, if you are facing a drug test and want to be certain, the sensible thing to do is declare your prescription before the test — most testing programmes have a simple medical-review process for prescribed medicines. Tirzepatide is a prescription-only medicine in the UK, which means a prescriber has already assessed whether it is appropriate for you; having that paperwork to hand makes any disclosure straightforward.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The decision most people are really making here is whether to declare their medication before a test, or to say nothing and hope for the best. To make that call confidently, it helps to understand what drug tests are actually looking for.
Standard workplace urine screens (the kind used by employers, probation services and many sports bodies) are immunoassay panels designed to detect specific substance classes: opioids, amphetamines, cocaine metabolites, cannabinoids, benzodiazepines and a handful of others. They work by recognising particular molecular shapes. Tirzepatide is a large peptide molecule, structurally unrelated to any of those classes. It does not bind to the antibodies the test uses. It produces no metabolite that resembles a controlled drug. The NHS medicines page for tirzepatide lists its side effects and interactions in detail; a false positive drug test does not appear among them, because there is no known mechanism by which it would occur.
A quick habit worth building: before any test, check whether the testing body has a Medical Review Officer (MRO) process. Most accredited programmes do. You can usually declare prescribed medicines in writing the day before, it takes less than a minute to note your prescription number and the drug's name on the declaration form. That single step means a positive result for anything unexpected is reviewed in context, not acted on automatically.
For more background on how the medicine works and what it contains, the tirzepatide overview on our site covers the pharmacology without the jargon.
It is worth being concrete about this. The most widely used urine drug screen (the SAMHSA five-panel) tests for THC metabolites, cocaine metabolites, opiates, phencyclidine and amphetamines. Expanded panels add benzodiazepines, barbiturates, methadone, propoxyphene and similar compounds. What they share is that they are all small-molecule drugs, most of them derived from alkaloid or synthetic chemical families.
Tirzepatide belongs to a completely different category. It is a synthetic peptide (a chain of amino acids) that mimics gut hormones. Peptide therapeutics are not part of any standard screening panel's target list. The same is true of other GLP-1 medicines such as semaglutide. There is simply no cross-reactivity to exploit.
If you are curious about how tirzepatide compares to semaglutide more broadly, our page on the documented effects of Mounjaro sets out what the clinical evidence shows. And if you want to understand the specific question of whether Mounjaro shows up on a drug test at all, that page goes into further detail on the same topic from a slightly different angle.
Even knowing that tirzepatide should not trigger a false positive, the right move is still to disclose. This is not about caution for its own sake. It is about protecting yourself from any edge-case scenario: a lab error, a mislabelled sample, or an expanded panel you were not told about. Disclosure costs you nothing and gives you a clear paper trail.
Your prescriber can provide a letter confirming your medication, the dose and the clinical reason for it. At nume, every patient's prescription is issued and held by a GPhC-registered Independent Prescriber (not generated automatically) so documentation is always traceable and signed. If you need supporting paperwork, our support team is available seven days a week.
There is separate, more detailed guidance on what specific testing methods detect on our tirzepatide and drug testing page, including the difference between immunoassay screening and confirmatory GC-MS testing. For anyone who has been asked to take part in a tirzepatide monitoring or research panel, the tirzepatide test kit page is also relevant.
One final note: tirzepatide in the UK is sold as Mounjaro, a prescription-only medicine for weight management or type 2 diabetes. You can read more about the medicine on the Mounjaro overview page. If you are weighing up the private cost of treatment, the Mounjaro cost page explains what a legitimate prescription includes. And if you are ready to find out whether it is clinically suitable for you, a free consultation with our prescribers is the place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.